Partner With Us NRI

Biocon Ltd share Price Today

Company details

6M Return 39.28%
1Y Return 39.62%
Mkt Cap.(Cr) 41,084.53
Volume 4,460,873
Div Yield 0.15%
OI Chg %
Volume 4,460,873

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Steady performance; focus on Viatris integration...
About The Stock

    Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene). Biocon Biologics (BBL), a subsidiary of Biocon, entered into an arrangement to acquire Viatris’ biosimilars assets for US$3.34 billion. Biocon Biologics entered into a strategic alliance with SILS for access to 100 million vaccine doses per annum for 15 years.

    • Biosimilar US pipeline: (approvals - bPegfilgrastim, bTrastuzumab, bGlargine, bAdalimumab)
    • In generics, among the world’s largest manufacturers of immunosuppressant and statin APIs
    • Revenue breakup Q3FY23: Biosimilars (50%), Generics (26%), CRAMS (24%)

    Numbers incorporating Viatris (November 29, 2023 cut-off date)

    • Revenues grew 35.3% YoY to ₹ 2941.1 crore
    • EBITDA margins declined 55 bps YoY to 21.9%. Overall EBITDA improved 32% YoY to ₹ 644.3 crore
    • Loss of ₹ 41.8 crore due to ₹ 271 crore of Viatris integration related expenses 

Click here for full recommendation

Research view on more stocks

Biotechnology company Biocon announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Biocon Q4FY24 reported consolidated revenue of Rs 3,966 crore with an EBITDA of Rs 964 crore.
  • The net profit for Q4FY24, before exceptional items, stood at Rs 144 crore.
  • Biocon Biologics' revenue for Q4FY24 was Rs 2,358 crore, marking an 18% growth.
  • Research services through Syngene contributed Rs 917 crore to the revenue.
  • Generics, including APIs and Generic Formulations, accounted for Rs 719 crore.

FY24 Financial Highlights:

  • FY24 revenue saw a significant 35% rise, reaching Rs 15,621 crore.
  • FY24 EBITDA and Net profit grew by 44% and 31%, respectively, with Biosimilars revenue crossing USD 1 billion.
  • Throughout FY24, Biosimilars produced a remarkable revenue of Rs 8,824 crore, witnessing a 58% increase.
  • Research Services saw an annual revenue of Rs 3,489 crore.
  • Generics marginally grew to Rs 2,799 crore for the financial year.
  • The Board has recommended a final dividend of Rs 0.50 per share for FY24.
  • Significant investment in R&D, with net expenses accounting for 10% of revenue in FY24.
  • Despite challenges in the U.S. biotech sector, Syngene's FY24 revenue incremented by 9%.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics said, BIOCON GROUP “Q4FY24 performance was strongly led by Biologics that delivered the promised billion-dollar annual revenue milestone marking the successful transition of the Biosimilars acquisition from Viatris. Increased market shares of key products in the U.S., Europe and Emerging Markets coupled with significant volumes growth were the highlights of the Biosimilars business this quarter. With the recent approval of Liraglutide in the UK, we added to our list of 'global firsts' and demonstrated our capability in developing complex GLP-1 products which will be the key growth driver for the Generics business, going forward. Syngene is well positioned to benefit from the ‘China Plus One’ strategy which is being rapidly adopted by U.S. Pharma & Biotech companies. 

For the full year FY24, we reported consolidated revenue growth of 35% at Rs 15,621 crore and an EBITDA growth of 44 % at Rs 4,164 crore with healthy EBITDA margins of 27%. This growth was largely driven by Biosimilars which grew 58% to Rs 8,824 crore.

The Biocon Group has strengthened business operations, expanded global reach and is now increasingly well positioned to deliver a new phase of growth spanning Biosimilars, GLP-1 peptides and CDMO services.”

Siddharth Mittal, CEO & Managing Director, Biocon said, “We concluded FY24 with the Generics business posting a modest revenue growth. Generic Formulations reported a healthy 36% growth, as our products, particularly statins and immunosuppressants, gained traction across multiple geographies. This was offset by a degrowth in APIs on account of pricing pressure the business encountered, which impacted demand.

Our preparations for entering the GLP-1 market opportunity is building momentum and we are pleased with the recent approval of Liraglutide in the UK, making Biocon the first generics Company to be approved for this product in an ICH or major regulated market. More importantly, the approval validates our scientific and development capability in bringing vertically integrated, complex peptide drug-device products to the market. This augurs well for us to capture GLP-1 opportunities that will drive our future growth.

Our focus in FY25 will be directed towards launching new products and expanding our geographic reach through a direct presence and strategic partnerships. We will continue to focus on multiple cost improvement initiatives. We also intend to build upon our initial regulatory success in our peptide and GLP-1 focused pipeline in strategic markets."

Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said, This has been a remarkable year for Biocon Biologics, as we evolved into a fully integrated global company with a presence in over 120 countries. We successfully integrated the acquired business 1 year ahead of plan, while ensuring business continuity and a seamless experience for our patients, customers, and partners. This is reflected in the numbers as our revenues crossed USD 1 billion for the full year with a healthy EBITDA margin, underpinned by a significant increase in market shares of our key products in the U.S., Europe, and Emerging Markets. Our R&D pipeline too has progressed as planned and having secured market entry dates for 2 new products in U.S. and Canada, these products will serve to accelerate growth in the coming years.

During the year, we reduced our acquisition debt. We also entered into a long-term strategic collaboration to distribute our products in India while retaining exclusive supply rights. FY24 has been a transformational year as we leverage our expanded global reach to address patient needs globally and unlock value for the benefit of all stakeholders."

Result PDF

View Other Company Results

Biocon Ltd shares SWOT Analysis

Strengths (6)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Strong Annual EPS Growth
  • Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Weakness (2)

  • MFs decreased their shareholding last quarter
  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (1)

  • RSI indicating price strength

Threats (1)

  • High PE (PE > 40)

Resistance and support

R1 346.1
R2 349.9
R3 354.5


S1 337.7
S2 333.1
S3 329.3
Delivery and volume
THE JUPITER GLOBAL FUND-JUPITER INDIA SELECT Block Purchase 2024-01-18 279.8 469049 BSE
AHAN - I LTD Bulk Sell 2023-03-17 200.74 18928363 NSE
Name Category Shares


Investment recommendation
Steady performance; focus on Viatris integration...
Call Date
16 Feb 2023
Entry Price 241.00
Target Price 230.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Biocon Ltd Stocks COMPARISON

Financials( in Cr) Biocon Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 342.20 1,494.50 1,504.40 4,519.55 1,080.35
% Change -1.01 1.86 -2.41 -0.06 -0.43
Mcap Cr 41,084.53 358,580.62 121,460.29 119,980.04 108,708.49
Revenue TTM Cr 11,174.20 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 643.00 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 39.83 35.84 28.50 74.97 28.20
1 Year Return 39.62 50.67 49.11 28.78 92.89
ROCE 5.68 16.79 14.76 19.30 16.25
ROE 6.64 16.46 10.66 14.89 14.05

Equity Capital: 17,866.90 Cr FV: 5.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 34,603.75 11,365.18
LAST 3M 103,254.09 -13,985.70
LAST 6M 182,650.74 -3,739.19
LAST 12M 295,819.56 101,589.49
Biocon Limited - Updates

Jun 24, 2024 l NSE Announcement

Biocon Limited - Updates

Jun 20, 2024 l NSE Announcement

Biocon Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Jun 19, 2024 l NSE Announcement

Date Action Type Ratio
Jul 05, 2024 Dividend 10
Jul 07, 2023 Dividend 30
Jun 30, 2022 Dividend 10

Biocon Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
Registered Address

20th KM Hosur Road Hebbagodi, Electronic City P O, Bangalore, Karnataka, 560100

Tel : 91-80-28082808
Email : co.secretary:biocon.com
Website : http://www.biocon.com

Karvy Computershare Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 532523
Book Closure Date (Month) :
BSE Group : A
ISIN : INE376G01013

FAQ’s on Biocon Ltd Shares

You can buy Biocon Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Biocon Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 24, 2024 03:59 PM the closing price of Biocon Ltd was Rs.342.20.

The latest PE ratio of Biocon Ltd as of Jun 24, 2024 03:59 PM is 39.83

The latest PB ratio of Biocon Ltd as of Jun 24, 2024 03:59 PM is 0.48

The 52-week high of Biocon Ltd share price is Rs. 351.00 while the 52-week low is Rs. 217.50

According to analyst recommendations, Biocon Ltd Share has a "Buy" rating for the long term.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 24, 2024 03:59 PM, the market cap of Biocon Ltd stood at Rs. 41,084.53 Cr.

Download App

Download Our App

Play Store App Store
market app